Oral N-acetylcysteine for Retinitis Pigmentosa

• Status: Not yet recruiting
• Trial end date: 2028-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Retinitis pigmentosa (RP) is an inherited retinal degeneration caused by one of several mistakes in the genetic code. Such mistakes are called mutations. The mutations cause degeneration of rod photoreceptors which are responsible for vision in dim illumination resulting in night blindness. After rod photoreceptors are eliminated, gradual degeneration of cone photoreceptors occurs resulting in gradual constriction of side vision that eventually causes tunnel vision. Oxidative stress contributes to cone degeneration. N-acetylcysteine (NAC) reduces oxidative stress and in animal models of RP it slowed cone degeneration. In a phase I clinical trial in patients with RP, NAC taken by month for 6 months caused some small improvements in two different vision tests suggesting that long-term administration of NAC might slow cone degeneration in RP. NAC Attack is a clinical trial being conducted at many institutions in the US, Canada, Mexico, and Europe designed to determine if taking NAC for several years provides benefit in patients with RP.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Collaborators: Centro Medico ABC; Duke University; Emory University; Massachusetts Eye and Ear Infirmary; Mayo Clinic; McGill University; Medical College of Wisconsin; Medical University of Graz; National Eye Institute (NEI); Northwestern University; Radboud University Medical Center; Retina Foundation of the Southwest; Stanford University; Universität Tübingen; University College London Hospitals; University Hospital, Basel, Switzerland; University of Amsterdam; University of California, Davis; University of Florida; University of Houston; University of Illinois at Chicago; University of Iowa; University of Miami; University of Michigan; University of Minnesota; University of Oklahoma; University of Southern California; University of Utah; University of Washington; University of Wisconsin, Madison; Vanderbilt University; Vitreo Retinal Associates, PA
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

General

• Ability and willingness to provide informed consent

• Age ≥ 18 and ≤65 years at time of signing Informed Consent Form

• Ability and willingness to comply with the study protocol and to participate in all study visits and assessments in the investigator's judgement

• For candidates of childbearing potential: willingness to use a method of contraception

• Agreement not to take supplements other than vitamin A

Ocular Inclusion Criteria

• Both eyes must exhibit the RP phenotype with evidence of loss of night vision, gradual constriction of visual fields, and maintenance of visual acuity;

• In addition, an eye must meet the following criteria to be included in the study:

• Gradable EZ on a horizontal SD-OCT scan through the fovea center with width ≤ 8000 µm and ≥1500 µm and with well-defined truncation at both the nasal and temporal sides;

• BCVA ≥ ETDRS letter score of 61 (20/60 Snellen equivalent);

• Sufficiently clear ocular media and adequate pupillary dilation to allow good quality images sufficient for analysis and grading by central reading center.

Exclusion Criteria:

General Exclusion Criteria

• Active cancer within the past 12 months, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with Gleason score ≤ 6 and stable prostate specific antigen for > 12 months

• Renal failure requiring renal transplant, hemodialysis, peritoneal dialysis, or anticipated to require hemodialysis or peritoneal dialysis during the study

• Liver disease, cystic fibrosis, asthma, or chronic obstructive pulmonary disease (COPD), history of thrombocytopenia not due to a reversible cause or other blood dyscrasia

• Uncontrolled blood pressure (defined as systolic > 180 and/or diastolic > 100 mmHg while at rest) at screening. If a patient's initial measurement exceeds these values, a second reading may be taken 30 or more minutes later. If the patient's blood pressure must be controlled by antihypertensive medication, the patient may become eligible if medication is taken continuously for at least 30 days.

• History of other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion that oral NAC may be contraindicated or that follow up may be jeopardized

• Cerebrovascular accident or myocardial infarction within 6 months of screening

• Participation in an investigational study that involves treatment with any drug or device within 6 months of screening

• Three relatives already enrolled in study

• Pregnant, breast feeding, or intending to become pregnant during the study treatment period. Women of childbearing potential who have not had tubal ligation must have a urine pregnancy test at screening.

• Known history of allergy to NAC

• Having taken NAC in any form in the past 4 months

• Phenylketonuria

• Fructose intolerance

• Glucose-galactose malabsorption

• Sucrase-isomaltase insufficiency

• Abnormal laboratory value including the value of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin being greater than 1.5 x the upper limit of normal

• Any major abnormal findings on blood chemistry, hematology, and renal function lab tests that in the opinion of the Site Investigator and/or the Study Chair makes the candidate not suitable to participate in the trial

• HIV or hepatitis B infection

Ocular Exclusion Criteria

• Evidence of cone-rod dystrophy or pattern dystrophy including focal areas of atrophy or pigmentary changes in the central macula

• Cystoid spaces involving the fovea substantially reducing vision

• Glaucoma or other optic nerve disease causing visual field loss or reduced visual acuity

• Intra ocular pressure >27 mm Hg from two measurements. If a patient's initial measurement exceeds 27 mm Hg, a second reading must be taken.

• Any retinal disease other than RP causing reduction in visual field or visual acuity

• Any prior macular laser photocoagulation

• Intraocular surgery within 3 months prior to screening

• High myopia with spherical equivalent refractive error > 8 diopters. If an eye has had cataract surgery or refractive surgery, a pre-operative refractive error spherical equivalent > 8 diopters is an exclusion

• Any concurrent ocular condition that might affect interpretation of results

• History of uveitis in either eye